Advertisement
Screener

MEREO BIOPHARMA GROUP PLC (MREO) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

2.1 / 5 stars · 12/29 Roast Me

MEREO BIOPHARMA GROUP PLC Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

MEREO BIOPHARMA GROUP PLC (MREO) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$8.68 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-26.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets

us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2025-03-26

  • MEREO BIOPHARMA GROUP PLC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$8.68M.
  • MEREO BIOPHARMA GROUP PLC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$9.10M, a 162.68% decline from fiscal 2022.
  • MEREO BIOPHARMA GROUP PLC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $14.52M.
Period endValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 monthValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed
2024-12-31-$8.68M
10-K · filed 2025-03-26
2023-12-31-$9.10M
10-K · filed 2025-03-26
$9.10M
10-K · filed 2024-03-27
2022-12-31$14.52M
10-K · filed 2024-03-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78